KRAS mutations in patients with AML: clinical characteristics and not reported mutations using NGS

References

• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi: 10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Cortes JE. Mutations in AML: prognostic and therapeutic implications. Hematology Am Soc Hematol Educ Program. 2016;2016(1):348–355. doi: 10.1182/asheducation-2016.1.348
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209–2221. doi: 10.1056/NEJMoa1516192
   PubMed Web of Science ®Google Scholar
• Leisch M, Jansko B, Zaborsky N, et al. Next generation sequencing in AML-On the way to becoming a new standard for treatment initiation and/or modulation? Cancers (Basel). 2019;11(2):252. doi: 10.3390/cancers11020252
   PubMed Web of Science ®Google Scholar
• Bhatnagar B, Garzon R. The use of molecular genetics to refine prognosis in acute myeloid leukemia. Curr Hematol Malig Rep. 2014;9(2):148–157. doi: 10.1007/s11899-014-0208-3
   PubMed Web of Science ®Google Scholar
• Shumilov E, Flach J, Kohlmann A, et al. Current status and trends in the diagnostics of AML and MDS. Blood Rev. 2018;32(6):508–519. doi: 10.1016/j.blre.2018.04.008
   PubMed Web of Science ®Google Scholar
• Mo SP, Coulson JM, Prior IA. RAS variant signalling. Biochem Soc Trans. 2018;46(5):1325–1332. doi: 10.1042/bst20180173
   PubMedGoogle Scholar
• Akram AM, Chaudhary A, Kausar H, et al. Analysis of RAS gene mutations in cytogenetically normal de novo acute myeloid leukemia patients reveals some novel alterations. Saudi J Biol Sci. 2021;28(7):3735–3740. doi: 10.1016/j.sjbs.2021.04.089
   PubMed Web of Science ®Google Scholar
• Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. Cancer Res. 2020;80(14):2969–2974. doi: 10.1158/0008-5472.can-19-3682
   PubMed Web of Science ®Google Scholar
• Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012;120(17):3397–3406. doi: 10.1182/blood-2012-05-378596
   PubMed Web of Science ®Google Scholar
• Neubauer A, Maharry K, Mrózek K, et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a cancer and leukemia group B study. J Clin Oncol. 2008;26(28):4603–4609. doi: 10.1200/jco.2007.14.0418
   PubMed Web of Science ®Google Scholar
• Kirkpatrick, A simple guide to IBM SPSS statistics for version 20.0. 213; 2013 https://search.worldcat.org/title/A-simple-guide-to-IBM-SPSS-statistics-for-version-20.0/oclc/793220809
   Google Scholar
• Gholami M, Bayat S, Pashaiefar H, et al. Mutational screening of RTK-BRAF genes in de novo adult acute myeloid leukemia. Gene Rep. 2020;21:100904. doi: 10.1016/j.genrep.2020.100904
   Web of Science ®Google Scholar
• Cuervo-Sierra J, Perez J, Martínez-Hernández R, et al. Prevalence and clinical significance of FLT3 mutation status in acute myeloid leukemia patients in two Latin American countries: a multicenter study. Arch Med Res. 2016;47(3):1–9. doi: 10.1016/j.arcmed.2016.06.003
   PubMed Web of Science ®Google Scholar
• Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021;11(5):104. doi: 10.1038/s41408-021-00495-3
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. doi: 10.1182/blood.2022016867
   PubMed Web of Science ®Google Scholar
• Barletta E et al. (2004). Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents. Carcinogenesis, 25(5), 749–55. 10.1093/carcin/bgh057
   PubMed Web of Science ®Google Scholar
• Thol F, Damm F, Lüdeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011;29(21):2889–2896. doi: 10.1200/jco.2011.35.4894
   PubMed Web of Science ®Google Scholar
• Lin J, Yao DM, Qian J, et al. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One. 2011;6(10):e26906. doi: 10.1371/journal.pone.0026906
   PubMed Web of Science ®Google Scholar
• Zhou JD, Yao DM, Li XX, et al. KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia. Oncotarget. 2017;8(39):66087–66097. doi: 10.18632/oncotarget.19798
   PubMedGoogle Scholar
• Barletta E, Gorini G, Vineis P, et al. Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents. Carcinogenesis. 2004;25(5):749–755. doi: 10.1093/carcin/bgh057
   PubMed Web of Science ®Google Scholar